<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20221212145353+01'00'</creation_date><modification_date>D:20221212145429+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-18-1299_h_epar-other_3.pdf</pdf_file></head><body><section><header>official address  domenico scarlattilaan 6  ●  1083 hs amsterdam  ●  the netherlands an agency of the european union     address for visits and deliveries  refer to www.ema.europa.eu/how-to-find-us  send us a question  go to www.ema.europa.eu/contact  telephone +31 (0)88 781 6000   © european medicines agency, 2022. reproduction is authorised provided the source is acknowledged. 
 23 june 2022 ema/936726/2022  
 committee for medicinal products for human use (chmp) 
 scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) 
  active substance(s): axicabtagene ciloleucel procedure no. emea/h/c/psusa/00010703/202110 
 period covered by the psur: 18 april 2021 to 17 october 2021 
      scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)  
 ema/936726/2022
  
 page 2/2</header></section><section><header>scientific conclusions</header><p>taking into account the prac assessment report on the psur(s) for axicabtagene ciloleucel, the scientific conclusions of chmp are as follows:</p><p>
 in view of available data on status epilepticus from ongoing clinical trials, the literature, spontaneous 
 reports including in some cases a close temporal relationship and in view of a plausible mechanism of 
 action, the prac considers a causal relationship between axicabtagene ciloleucel and status epilepticus 
 is at least a reasonable possibility. the prac concluded that the product information of products 
 containing axicabtagene ciloleucel should be amended accordingly. 
 the chmp agrees with the scientific conclusions made by the prac.</p></section><section><header>grounds for the variation to the terms of the marketing authorisation(s)</header><p>on the basis of the scientific conclusions for axicabtagene ciloleucel the chmp is of the opinion that the benefit-risk balance of the medicinal product(s) containing axicabtagene ciloleucel is unchanged 
 subject to the proposed changes to the product information 
 the chmp recommends that the terms of the marketing authorisation(s) should be varied.</p></section></body></xml>